Table 2

Measurement of changes in catastrophizing in studies using the Pain Catastrophizing Scale*

StudyMean scoreChangeStudy period
InitialFinal
Alappattu26188−10.0NR
Barker et al.2719.618−1.63 wk
Baudic et al.2814.621.5+6.91 yr
Bostick et al.2922.217.8−4.46 mo
Chmielewski et al.313.72.5−1.29 wk
Chmielewski et al.3211.24−7.212 wk
Clarke et al.3319.513.0−6.52 h after drug administration
Eyer et al.36NRNR−11.812 mo
Forsythe et al.389.89.80.02 yr
Hirakawa et al.40139.3−3.73 wk
Høvik et al.518.27.6†−10.6†
Khan et al.611.6910.84−0.5948 h
Lee et al.4528.112.7−15.412 mo
Lluch et al.4622.66−16.65 mo
Louw et al.472313−101 d
Martorella et al.491.041.19+0.157 d
Miyazaki et al.5024.27.1−14.13 mo
Monticone et al.5124.812.6−12.21 yr
Ostelo et al.5216.9NR−7.31 yr
Riddle et al.5629.710.1−19.62 mo
Tetsunaga et al.5834.428−5.46 mo
Tetsunaga et al.5933.728.9−4.86 mo
Tichonova et al.615.23.8−1.4Unclear (“after rehabilitation complete”)
Vranceanu et al.6514.83.8−11.04–6 wk
Wade et al.66147.32−6.686 mo
Wideman et al.6925.417.45−7.95NR

  • NR = not reported.

  • ↵* Only studies in which the study period was reported are included.

  • ↵† Median.